Middle East & Africa Genomics Market Outlook to 2030

Region:Middle East

Author(s):Sanjana

Product Code:KROD2769

Published On

October 2024

Total pages

98

About the Report

Middle East & Africa Genomics Market Overview

  • Middle East & Africa Genomics Market was valued at USD 1.2 billion in 2023, driven by advancements in precision medicine, personalized healthcare, and increasing adoption of genomics technologies in research and clinical settings. Key factors include expanding research funding, growing demand for genomic sequencing, and applications in agriculture, pharmaceuticals, and diagnostics.
  • Major players in the MEA Genomics Market include Illumina Inc., Thermo Fisher Scientific Inc., BGI Genomics Co., Agilent Technologies, and Qiagen N.V. These companies dominate the market by offering comprehensive genomics solutions, including sequencing platforms, reagents, and analysis tools.
  • In 2023, Thermo Fisher Scientific recently announced a collaboration with Pfizer to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia. This partnership aims to make advanced genomic testing more widely available in regions where it has previously been limited or unavailable.
  • Cities like Dubai, Tel Aviv, and Johannesburg dominate the MEA genomics market due to their advanced healthcare infrastructure and investment in cutting-edge research facilities. These cities house leading universities, research institutions, and biotechnology companies that drive innovation and adoption of genomic technologies.

Middle East & Africa Genomics Market Size

Middle East & Africa Genomics Market Segmentation

By Product Type: The MEA Genomics Market is segmented by product type into sequencing platforms, consumables, and bioinformatics tools. In 2023, sequencing platforms held a dominant market share due to their widespread use in research and clinical applications. The integration of NGS platforms for disease diagnostics and research on genetic mutations has propelled the demand for these technologies.

Middle East & Africa Genomics Market Share

By Application: The genomics market in MEA is segmented by application into diagnostics, drug discovery, and agriculture genomics. Diagnostics dominate the segment in 2023, accounting for the largest market share due to the growing demand for genetic testing for cancer, rare diseases, and prenatal screening. Genetic testing for cancer treatments, particularly in South Africa and Israel, has seen a sharp increase, driven by government healthcare programs and growing awareness of personalized medicines benefits.

Middle East & Africa Genomics Market Segmentation

By Region: MEA Genomics Market is segmented into Israel, UAE, Jordan, Morocco, South Africa, and the rest of MEA. In 2023, Israel held the largest market share due to its advanced research institutions and significant investments in biotechnology. The countrys strong innovation ecosystem, supported by government funding and partnerships between academia and industry, has placed it at the forefront of genomics research and commercialization.

Middle East & Africa Genomics Market Competitive Landscape

Company

Establishment Year

Headquarters

Illumina Inc.

1998

San Diego, USA

Thermo Fisher Scientific

1956

Waltham, USA

BGI Genomics Co.

1999

Shenzhen, China

Agilent Technologies

1999

Santa Clara, USA

Qiagen N.V.

1984

Venlo, Netherlands

  • Illumina Inc.: In 2024, Illumina is collaborating with the Abu Dhabi Department of Health to integrate genomics into the standard of care in the UAE. This partnership is part of Illumina's broader efforts to enhance genomic testing and research capabilities across the Middle East and Africa (MEA) region, aiming to improve healthcare outcomes through advanced genomic insights.
  • BGI Genomics: In 2023, Genalive, a clinical laboratory in Saudi Arabia, has achieved CAP accreditation, showcasing its high standards in laboratory testing and management. Genalive utilizes advanced technologies and a skilled team to offer services like genetic screening and oncology. The CAP audit confirmed its excellence in various operational aspects, supporting Saudi Vision 2030 by enhancing local healthcare capabilities and reducing service outsourcing.

Middle East & Africa Genomics Industry Analysis

Growth Drivers:

  • Rising Demand for Genetic Testing in Healthcare: Between 2021 and 2024, the demand for genetic testing in the healthcare sector across the Middle East & Africa has increased significantly, particularly for diagnosing hereditary diseases and cancer. The demand for specific types of genetic testing, such as prenatal testing and non-invasive screening, is on the rise. For instance, several countries in the region have mandated premarital screening for hemoglobinopathies, significantly reducing the prevalence of conditions like sickle cell disease in Bahrain.
  • Expanding Agricultural Genomics in Africa: Current trends indicate that annual yield increases for major crops range between 0.9% and 1.6%. However, to meet future global food demands, an estimated 2.4% annual yield gain is required. The use of genomic data in developing disease-resistant crops is helping to tackle food security issues in Africa, making this a vital sector of the genomics market.
  • Increased Government Funding for Genomic Research: Governments across the Middle East are actively funding genomics research as part of their national healthcare improvement plans. The Emirati Genome Program (EGP) was launched in 2021 with a target of sequencing 1,000,000 genomes. As of 2022, they have sequenced 180,000 samples, which is 15.52% of their target population size. This influx of funding aims to support the local biotechnology and healthcare industries in improving patient outcomes.

Challenges:

  • High Costs of Genomic Sequencing Technologies: Despite the advancements, the high cost of genomic sequencing remains a significant barrier to broader adoption across the MEA region. The lack of cost-effective alternatives in low-income regions, especially in Africa, has slowed the adoption of genomics-based solutions in public healthcare, limiting their accessibility to wealthier countries in the Middle East.
  • Data Privacy and Ethical Concerns: As the demand for genomic data grows, so do concerns about data privacy and ethical use. Governments in the Middle East, particularly in the UAE and Israel, have introduced stringent regulations to protect genomic data. However, concerns remain over potential misuse of genetic data, especially in countries without strong regulatory frameworks, presenting an ongoing challenge for the market.

Government Initiatives:

  • Emirati Genome Program: The Emirati Genome Program was launched in the first trimester of 2021. This initiative aims to generate deep genomic insights relevant to the Emirati population and is part of a broader strategy to enhance healthcare through personalized medicine and preventive measures. The program includes the UAE Reference Genome study, which analyzes over 50,000 genome samples to identify genetic health risks specific to the Emirati population. This foundational work will support personalized treatment and preventive healthcare strategies.
  • Africa Pathogen Genomics Initiative: The Africa Pathogen Genomics Initiative (Africa PGI) was launched on 2020. The initiative aims to enhance genomic surveillance and molecular diagnostics across Africa, contributing significantly to public health responses to various diseases, including COVID-19 and endemic diseases like HIV/AIDS, tuberculosis, and malaria. The goal is to mortify multi-pathogen molecular detection and sequencing capabilities in African Union member states.

Middle East & Africa Genomics Future Market Outlook

Middle East & Africa Genomics Market is expected to witness significant growth over the next five years, driven by increasing government investments, rising demand for personalized medicine, and expanding applications in agriculture.

Future Trends

  • Advancement in Precision Medicine: Precision medicine is expected to become a key focus in the MEA genomics market, particularly in Israel and the UAE. With continued government support, genomic data will be increasingly integrated into healthcare systems to provide personalized treatment options for chronic diseases like cancer and diabetes. This trend will drive the adoption of genomic sequencing in public healthcare programs across the region.
  • Growth in Agricultural Genomics: The application of genomics in agriculture is projected to grow significantly, especially in Africa. countries like South Africa and Morocco will lead in using genomic technologies to enhance crop yields and improve food security. The focus will be on developing genetically modified crops that are resistant to climate change and pests, ensuring sustainable agricultural practices in the region.

Scope of the Report

Middle East & Africa Genomics Market Segmentation

By Product Type

Sequencing Platforms

Consumables

Bioinformatics Tools

By Application

Diagnostics

Drug Discovery

Agriculture Genomics

By Region

Israel

United Arab Emirates (UAE)

Jordan

Morocco

South Africa

Rest of MEA

Products

Key Target Audience Organizations and Entities Who Can Benefit by Subscribing This Report:

  • Pharmaceutical Companies

  • Biotechnology Firms

  • Healthcare Providers

  • Genetic Testing Companies

  • Genomic Data Management Firms

  • Investors and Venture Capitalist Firms

  • Government and Regulatory Bodies (UAE Ministry of Health, South Africa Department of Health)

Time Period Captured in the Report:

  • Historical Period: 2018-2023

  • Base Year: 2023

  • Forecast Period: 2023-2028

Companies

Major Players Mentioned in the Report:

  • Illumina Inc.

  • Thermo Fisher Scientific Inc.

  • BGI Genomics Co.

  • Agilent Technologies

  • Qiagen N.V.

  • Oxford Nanopore Technologies

  • PerkinElmer Inc.

  • Pacific Biosciences

  • Roche Diagnostics

  • Bio-Rad Laboratories

  • Eurofins Genomics

  • GE Healthcare

  • 10x Genomics

  • Integrated DNA Technologies

  • GenScript Biotech Corporation

Table of Contents

1. Middle East & Africa Genomics Market Overview

1.1. Definition and Scope

1.2. Market Growth Rate (in %)

1.3. Market Drivers (technological advancements, precision medicine adoption, personalized healthcare)

1.4. Market Segmentation Overview

2. Middle East & Africa Genomics Market Size (in USD Bn)

2.1. Historical Market Size

2.2. Key Market Developments and Milestones

2.3. Future Market Projections

3. Middle East & Africa Genomics Market Analysis

3.1. Growth Drivers

3.1.1. Increasing Research Funding

3.1.2. Advancements in Genomic Sequencing

3.1.3. Expanding Precision Medicine and Personalized Healthcare

3.2. Market Restraints

3.2.1. High Costs of Genomic Sequencing Technologies

3.2.2. Ethical and Data Privacy Concerns

3.2.3. Limited Access to Genomic Infrastructure in Low-Income Regions

3.3. Market Opportunities

3.3.1. Expansion of Genomics Applications in Agriculture

3.3.2. Partnerships Between Governments and Biotechnology Firms

3.3.3. Integration of Genomic Data into National Healthcare Programs

3.4. Market Trends

3.4.1. Growing Demand for Next-Generation Sequencing (NGS)

3.4.2. Genomic Research in Cancer and Rare Disease Diagnostics

3.4.3. Use of Genomics for Developing Disease-Resistant Crops

3.5. Competitive Landscape and SWOT Analysis

3.5.1. Strengths

3.5.2. Weaknesses

3.5.3. Opportunities

3.5.4. Threats

4. Middle East & Africa Genomics Market Segmentation

4.1. By Product Type (in value %)

4.1.1. Sequencing Platforms

4.1.2. Consumables

4.1.3. Bioinformatics Tools

4.2. By Application (in value %)

4.2.1. Diagnostics

4.2.2. Drug Discovery

4.2.3. Agricultural Genomics

4.3. By Region (in value %)

4.3.1. Israel

4.3.2. UAE

4.3.3. South Africa

4.3.4. Morocco

4.3.5. Rest of MEA

5. Middle East & Africa Genomics Competitive Landscape

5.1. Detailed Profiles of Major Companies

5.1.1. Illumina Inc. (San Diego, USA)

5.1.2. Thermo Fisher Scientific (Waltham, USA)

5.1.3. BGI Genomics Co. (Shenzhen, China)

5.1.4. Agilent Technologies (Santa Clara, USA)

5.1.5. Qiagen N.V. (Venlo, Netherlands)

5.1.6. F. Hoffmann-La Roche (Basel, Switzerland)

5.1.7. Oxford Nanopore Technologies (Oxford, UK)

5.1.8. PerkinElmer Inc. (Waltham, USA)

5.1.9. GE Healthcare (Chicago, USA)

5.1.10. Pacific Biosciences (Menlo Park, USA)

5.1.11. Eurofins Scientific (Luxembourg)

5.1.12. Danaher Corporation (Washington, D.C., USA)

5.1.13. Gencove Inc. (New York, USA)

5.1.14. MedGenome (Bangalore, India)

5.1.15. Strand Life Sciences (Bangalore, India)

5.2. Market Share Analysis (in %)

5.3. Key Strategic Initiatives

5.3.1. Mergers and Acquisitions

5.3.2. Strategic Partnerships and Collaborations

5.3.3. Investment Analysis

6. Middle East & Africa Genomics Market Regulatory Framework

6.1. Government Regulations (in specific MEA regions)

6.2. Compliance Requirements (data privacy, ethical standards)

6.3. Certification Processes for Genomics Labs and Institutions

7. Middle East & Africa Genomics Future Market Outlook

7.1. Future Market Size Projections (in USD Bn)

7.2. Key Factors Driving Future Market Growth

7.2.1. Government Investments in Genomics

7.2.2. Expansion of Precision Medicine Initiatives

7.2.3. Integration of Genomics in Agriculture and Food Security

8. Middle East & Africa Genomics Future Market Segmentation

8.1. By Product Type (in value %)

8.2. By Application (in value %)

8.3. By End-User (in value %)

8.4. By Region (in value %)

9. Middle East & Africa Genomics Market Analysts Recommendations

9.1. TAM/SAM/SOM Analysis (Total Addressable Market, Serviceable Available Market, Serviceable Obtainable Market)

9.2. White Space Opportunity Analysis

9.3. Marketing and Growth Initiatives

10. Contact Information

Research Methodology

Step 1: Identifying Key Variables:

Ecosystem creation for all the major entities and referring to multiple secondary and proprietary databases to perform desk research around market to collate industry level information.

Step 2: Market Building:

Collating statistics on Middle East & Africa Genomics Market over the years, penetration of marketplaces and service providers ratio to compute revenue generated for Middle East & Africa Genomics Market. We will also review service quality statistics to understand revenue generated which can ensure accuracy behind the data points shared.

Step 3: Validating and Finalizing:

Building market hypothesis and conducting CATIs with industry experts belonging to different companies to validate statistics and seek operational and financial information from company representatives.

Step 4: Research output:

Our team will approach multiple genomics companies and understand nature of product segments and sales, consumer preference and other parameters, which will support us validate statistics derived through bottom to top approach from genomics companies.

Frequently Asked Questions

01 How big is Middle East & Africa Genomics Market?

Middle East & Africa Genomics Market was valued at USD 1.2 billion in 2023, driven by advancements in precision medicine, personalized healthcare, and increasing adoption of genomics technologies in research and clinical settings.

02 What are the growth drivers of the Middle East & Africa Genomics market?

Middle East & Africa Genomics Market is driven by the increasing demand for genetic testing in healthcare, expanding applications in agricultural genomics, and substantial government funding for genomic research in countries like Israel and the UAE.

03 What are challenges in Middle East & Africa Genomics Market?

Challenges of Middle East & Africa Genomics Market include the high cost of genomic sequencing technologies, lack of skilled professionals, and data privacy concerns. Additionally, the limited infrastructure for genomic research in several African countries hampers market growth.

04 Who are major players in the Middle East & Africa Genomics Market?

Major players include Illumina Inc., Thermo Fisher Scientific, BGI Genomics Co., Agilent Technologies, and Qiagen N.V. These companies lead the market through innovation in sequencing technologies and strategic partnerships in the region.

Why Buy From Us?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

Our Reach Is Unmatched
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022